Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AmbAgon 14-3-3 stabilizer (vesicle trafficking)
- Development stage
- Preclinical
- Lead developer
- AmbAgon Therapeutics
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
AmbAgon Therapeutics is developing a small molecule 14-3-3 molecular glue stabilizer for the treatment of neurodegenerative diseases. This candidate, currently in the target validation stage of preclinical development, functions by stabilizing the protein-protein interaction between 14-3-3 adapter proteins and a specific structural protein involved in vesicle trafficking and neurotransmitter release. By enhancing or restoring the stability of these complexes, the drug aims to modulate the function of the target protein to address synaptic dysfunction and transport deficits characteristic of neurodegeneration. The program is being developed in collaboration with academic experts and targets a biological pathway with existing clinical competition.
- Other names
- AmbAgon Therapeutics-Structural protein (vesicle trafficking, neurotransmitter release)-small molecule-Neurodegeneration
02
Targets
SFN (Protein kinase C inhibitor protein 1)
Beyond the preview
Go deeper on AmbAgon 14-3-3 stabilizer (vesicle trafficking).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AmbAgon 14-3-3 stabilizer (vesicle trafficking).